Action Potential Venture Capital

Action Potential Venture Capital

Dedicated to bringing bioelectronic medicines to patients

APVC is a leading medical technology venture capital firm founded by GSK in 2013 We invest around the world and take a hands-on role on the boards of start-ups advancing bioelectronic medicines and their enabling technologies

We believe in the fundamental advantage of an inclusive and diverse workspace and are committed to creating a more equitable healthcare investor and entrepreneurial community Our commitment begins at APVC through the diversity of the investment team, and we extend this accountability to the companies we invest in

What Is Bioelectronic Medicine

Bioelectronic medicine is an emerging therapeutic field which leverages advances in hardware, computing and material science to regulate neural or cellular activity, and more effectively treat a range of chronic diseases

One important therapeutic target for bioelectronic medicines is the nervous system which carries electrical impulses – or action potentials – that control virtually every organ or function in our bodies The nervous system can be modulated to treat diseases through the targeted delivery of various forms of energy including electrical, electromagnetic, and acoustic energy

APVC's first Diversity, Equity & Inclusion Survey Report Saluda Medical Announces Presentation of 36-Month Trial Data at NANS 2023 Annual Meeting SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company's Novel Treatment for Autoimmune Diseases This website and the contact information contained therein is not intended for reporting adverse events If you have a question about a GSK product or want to report a side effect, please call the GSK Response Center at 1-888-825-5249 Monday-Friday, 8:00 am - 6:00 pm ET This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply